Maven Semantic: Database of Bioavailability / Bioequivalence Professionals

Search Over 30,000 People and Over 2,000 Organisations Involved in Bioavailability / Bioequivalence

DUBLIN--(BUSINESS WIRE)-- Maven Semantic (http://www.mavensemantic.com) announces updates to their Bioavailability / Bioequivalence database.

The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

The database currently tags 30,000 individuals working in Bioavailability / Bioequivalence. http://bit.ly/bD7NBR.

Top 10 Countries for Bioavailability / Bioequivalence Studies (ranked by number of Bioavailability / Bioequivalence researchers)

. United States Of America (12,059)

. United Kingdom (1,751)

. Germany (1,510)

. France (1,180)

. Japan (1,166)

. China (1,116)

. Italy (951)

. Canada (897)

. Spain (699)

. India (688)

Leading organisations in Bioavailability / Bioequivalence include:

. University of California

. Chinese Academy of Sciences

. University of Florida

. National Institutes of Health

. Harvard Medical School

. Shenyang Pharmaceutical University

. Seoul National University

. University of Toronto

. Cornell University

. Ghent University

. National Cancer Institute

. University of Kentucky

. Mayo Clinic

. North Carolina State University

. University of Manchester

. Center for Drug Evaluation and Research

. Brigham and Women's Hospital

. Massachusetts General Hospital

. National University of Singapore

. Pharmaceutical Research Institute

. Emory University School of Medicine

. Institute of Food Research

The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Bioavailability / Bioequivalence research field.

Sample companies in database include:

. Pfizer Inc

. Bristol-Myers Squibb Company

. F. Hoffmann-La Roche Ltd

. Gilead Sciences, Inc

. Amgen Inc

. Eli Lilly and Company

. Upjohn Company

. Bayer AG

. Yamanouchi Pharmaceutical Co., Ltd

. Bristol Myers Squibb Company

. Genentech, Inc

. Astellas Pharma Inc

. Boehringer Ingelheim (Canada) Ltd

. Merck & Co., Inc

. Novartis Pharmaceuticals Corporation

. Fujisawa Pharmaceutical Co., Ltd

. Mitsubishi Pharma Corporation

. Warner-Lambert Company

. Sandoz Pharma Ltd

. Chroma Therapeutics Ltd

. Hoechst AG

. Banyu Pharmaceutical Co., Ltd

. Neurocrine Biosciences, Inc

. Genetic Therapy, Inc

. Shinogi & Co., Ltd

. CoCensys, Inc

. Medivir AB

. Metabasis Therapeutics, Inc

. Pharmacyclics, Inc

. Pharmakin GmbH

. Suven Life Sciences Ltd

. ViroPharma, Inc

. Xencor, Inc

. Basilea Pharmaceutica, Ltd

. Desitin Arzneimittel GmbH

. EGIS Pharmaceuticals Ltd

. Lek Pharmaceuticals d.d

What is Maven:

- Largest database of international medical professionals, with over 5,600,000 people and over 500,000 medical organisations;

- All records are downloadable to excel or in-house database, with email, postal address and phone contacts;

- Profile and segment the entire database using over 47,000 diseases and therapeutic areas

What is Maven used for:

- Building prospect lists for postal, telesales and email campaigns

- Locating key decision makers in companies, hospitals, government labs, university labs, and other healthcare facilities

- Identifying candidates for recruitment to very specific life science positions

About the Maven Semantic Medical Database: The current database holds over 5 million medical professionals, and 500,000 medical organisations.

The Maven Semantic medical database covers pharmaceutical, biotech and medical device companies, clinical research labs, hospitals, medical universities and government research organisations.

Maven is a SaaS subscription-based service. Clients can choose from quarterly or yearly subscriptions, or as pay-as-you-go option to retrieve specific large datasets for in-house use.

Results can be viewed online, or exported to Excel or a CRM system.

The data is now available to international healthcare marketing teams.

About our Technology: Semantic data mining tools have been used to create a database of detailed profiles of life science companies and executives.

The system uses the open web as an underlying database and extracts specific information on people, job titles, biographies, research profiles, contact details (dept., phone, fax, and email), organisation profiles, websites, product/services and much more.

Maven is based on healthcare crawlers/bots, search technology, semantic parsers, clustering, natural language processing (NLP) and artificial intelligence (AI) technology.

"The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - for example, how important is this person in a specific medical research specialization," says Alejandro Mesas, Semantic Systems Architect. "The big advantage of a focused semantic healthcare database over a generic search engine is that it has built-in taxonomies and a thesaurus to expand and refine the user queries. We then use scoring and ranking to fine tune the relevance of the results for a given therapeutic area. For example, stem cell researchers are given a "page rank", based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the user".

For more information visit http://www.mavensemantic.com/.



CONTACT:

Maven Semantic
Bryan McManmon, + 353 1 4100699 or + 353 1 4100699
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Technology  Data Management  Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.